Interleukin 6 and complement serum level study in Parkinson's
disease

J 2018

Interleukin 6 and complement serum level study in Parkinson's disease

VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA et. al.

Základní údaje

Originální název

Interleukin 6 and complement serum level study in Parkinson's disease

Autoři

VESELÝ, Branislav (703 Slovensko, domácí), Michal DUFEK (203 Česká republika, domácí), Vojtěch THON (203 Česká republika, domácí), M. BROZMAN (703 Slovensko), S. KIRALOVA (703 Slovensko), T. HALASZOVA (703 Slovensko), Eva KORIŤÁKOVÁ (203 Česká republika, domácí) a Ivan REKTOR (203 Česká republika, garant, domácí)

Vydání

Journal of Neural Transmission, WIEN, SPRINGER WIEN, 2018, 0300-9564

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30103 Neurosciences

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.903

Kód RIV

RIV/00216224:14740/18:00103549

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1007/s00702-018-1857-5

UT WoS

000430583400010

Klíčová slova anglicky

Complement; Interleukin 6; Parkinson's disease

Štítky

14110114, 14110127, 14119612, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 3. 2019 13:37, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA, T. HALASZOVA, Eva KORIŤÁKOVÁ a Ivan REKTOR. Interleukin 6 and complement serum level study in Parkinson's disease. Journal of Neural Transmission. WIEN: SPRINGER WIEN, 2018, roč. 125, č. 5, s. 875-881. ISSN 0300-9564. Dostupné z: https://dx.doi.org/10.1007/s00702-018-1857-5.

@article{1431177,
   author = {Veselý, Branislav and Dufek, Michal and Thon, Vojtěch and Brozman, M. and Kiralova, S. and Halaszova, T. and Koriťáková, Eva and Rektor, Ivan},
   article_location = {WIEN},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s00702-018-1857-5},
   keywords = {Complement; Interleukin 6; Parkinson's disease},
   language = {eng},
   issn = {0300-9564},
   journal = {Journal of Neural Transmission},
   title = {Interleukin 6 and complement serum level study in Parkinson's disease},
   url = {https://link.springer.com/article/10.1007%2Fs00702-018-1857-5},
   volume = {125},
   year = {2018}
}

TY  - JOUR
ID  - 1431177
AU  - Veselý, Branislav - Dufek, Michal - Thon, Vojtěch - Brozman, M. - Kiralova, S. - Halaszova, T. - Koriťáková, Eva - Rektor, Ivan
PY  - 2018
TI  - Interleukin 6 and complement serum level study in Parkinson's disease
JF  - Journal of Neural Transmission
VL  - 125
IS  - 5
SP  - 875-881
EP  - 875-881
PB  - SPRINGER WIEN
SN  - 03009564
KW  - Complement
KW  - Interleukin 6
KW  - Parkinson's disease
UR  - https://link.springer.com/article/10.1007%2Fs00702-018-1857-5
L2  - https://link.springer.com/article/10.1007%2Fs00702-018-1857-5
N2  - The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
ER  -

VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA, T. HALASZOVA, Eva KORIŤÁKOVÁ a Ivan REKTOR. Interleukin 6 and complement serum level study in Parkinson's disease. \textit{Journal of Neural Transmission}. WIEN: SPRINGER WIEN, 2018, roč.~125, č.~5, s.~875-881. ISSN~0300-9564. Dostupné z: https://dx.doi.org/10.1007/s00702-018-1857-5.

Podrobný výpis o publikaci